We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

5 hedge funds and large institutions have $18.9M invested in Celyad Oncology SA American Depositary Shares in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

18% more capital invested

Capital invested by funds: $16M → $18.9M (+$2.87M)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$314K
2
Zurich Cantonal Bank
Zurich Cantonal Bank
Switzerland
+$4.49K
3
TRCT
Tower Research Capital (TRC)
New York
+$404

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$2.12M
2
UBS Group
UBS Group
Switzerland
-$17.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
1
Victory Capital Management
Texas
$18.2M -$2.12M -47,280 -13%
Morgan Stanley
2
Morgan Stanley
New York
$597K +$314K +7,006 +197%
UBS Group
3
UBS Group
Switzerland
$49K -$17.2K -384 -31%
Zurich Cantonal Bank
4
Zurich Cantonal Bank
Switzerland
$6K +$4.49K +100 New
TRCT
5
Tower Research Capital (TRC)
New York
$2K +$404 +9 +45%

CYAD Hedge Fund Activity: Q3 2017 in Review

5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2017, worth a combined $18.9M — up 18% from $16M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CYAD positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $314K. The largest seller was Victory Capital Management, cutting an estimated $2.12M.

  • 5 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2017, up from 4 in Q2 2017.
  • Funds reported $18.9M of Celyad Oncology SA American Depositary Shares stock for Q3 2017, up 18% quarter-over-quarter.
  • 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q3 2017 and 0 closed out, a net change of +1 holder.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2017 was Morgan Stanley, an estimated $314K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q3 2017 was Victory Capital Management, an estimated $2.12M sold.

Based on aggregated 13F filings for Q3 2017.